RT Journal Article
SR Electronic
T1 Mapping the aetiological foundations of the heart failure spectrum using human genetics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.01.23296379
DO 10.1101/2023.10.01.23296379
A1 Henry, Albert
A1 Mo, Xiaodong
A1 Finan, Chris
A1 Chaffin, Mark D.
A1 Speed, Doug
A1 Issa, Hanane
A1 Denaxas, Spiros
A1 Ware, James S.
A1 Zheng, Sean L.
A1 Malarstig, Anders
A1 Gratton, Jasmine
A1 Bond, Isabelle
A1 Roselli, Carolina
A1 Miller, David
A1 Chopade, Sandesh
A1 Schmidt, A. Floriaan
A1 Abner, Erik
A1 Adams, Lance
A1 Andersson, Charlotte
A1 Aragam, Krishna G.
A1 Ärnlöv, Johan
A1 Asselin, Geraldine
A1 Axelsson Raja, Anna
A1 Backman, Joshua D.
A1 Bartz, Traci M.
A1 Biddinger, Kiran J.
A1 Biggs, Mary L.
A1 Bloom, Heather L.
A1 Boersma, Eric
A1 Brandimarto, Jeffrey
A1 Brown, Michael R.
A1 Brunak, Søren
A1 Bruun, Mie Topholm
A1 Buckbinder, Leonard
A1 Bundgaard, Henning
A1 Carey, David J.
A1 Chasman, Daniel I.
A1 Chen, Xing
A1 Cook, James P.
A1 Czuba, Tomasz
A1 de Denus, Simon
A1 Dehghan, Abbas
A1 Delgado, Graciela E.
A1 Doney, Alexander S.
A1 Dörr, Marcus
A1 Dowsett, Joseph
A1 Dudley, Samuel C.
A1 Engström, Gunnar
A1 Erikstrup, Christian
A1 Esko, Tõnu
A1 Farber-Eger, Eric H.
A1 Felix, Stephan B.
A1 Finer, Sarah
A1 Ford, Ian
A1 Ghanbari, Mohsen
A1 Ghasemi, Sahar
A1 Ghouse, Jonas
A1 Giedraitis, Vilmantas
A1 Giulianini, Franco
A1 Gottdiener, John S.
A1 Gross, Stefan
A1 Guðbjartsson, Daníel F.
A1 Gui, Hongsheng
A1 Gutmann, Rebecca
A1 Hägg, Sara
A1 Haggerty, Christopher M.
A1 Hedman, Åsa K.
A1 Helgadottir, Anna
A1 Hemingway, Harry
A1 Hillege, Hans
A1 Hyde, Craig L.
A1 Jensen, Bitten Aagaard
A1 Jukema, J. Wouter
A1 Kardys, Isabella
A1 Karra, Ravi
A1 Kavousi, Maryam
A1 Kizer, Jorge R.
A1 Kleber, Marcus E.
A1 Køber, Lars
A1 Koekemoer, Andrea
A1 Kuchenbaecker, Karoline
A1 Lai, Yi-Pin
A1 Lanfear, David
A1 Langenberg, Claudia
A1 Lin, Honghuang
A1 Lind, Lars
A1 Lindgren, Cecilia M.
A1 Liu, Peter P.
A1 London, Barry
A1 Lowery, Brandon D.
A1 Luan, Jian’an
A1 Lubitz, Steven A.
A1 Magnusson, Patrik
A1 Margulies, Kenneth B.
A1 Marston, Nicholas A.
A1 Martin, Hilary
A1 März, Winfried
A1 Melander, Olle
A1 Mordi, Ify R.
A1 Morley, Michael P.
A1 Morris, Andrew P.
A1 Morrison, Alanna C.
A1 Morton, Lori
A1 Nagle, Michael W.
A1 Nelson, Christopher P.
A1 Niessner, Alexander
A1 Niiranen, Teemu
A1 Noordam, Raymond
A1 Nowak, Christoph
A1 O’Donoghue, Michelle L.
A1 Ostrowski, Sisse Rye
A1 Owens, Anjali T.
A1 Palmer, Colin N. A.
A1 Paré, Guillaume
A1 Pedersen, Ole Birger
A1 Perola, Markus
A1 Pigeyre, Marie
A1 Psaty, Bruce M.
A1 Rice, Kenneth M.
A1 Ridker, Paul M.
A1 Romaine, Simon P. R.
A1 Rotter, Jerome I.
A1 Ruff, Christian T.
A1 Sabatine, Mark S.
A1 Sallah, Neneh
A1 Salomaa, Veikko
A1 Sattar, Naveed
A1 Shalaby, Alaa A.
A1 Shekhar, Akshay
A1 Smelser, Diane T.
A1 Smith, Nicholas L.
A1 Sørensen, Erik
A1 Srinivasan, Sundararajan
A1 Stefansson, Kari
A1 Sveinbjörnsson, Garðar
A1 Svensson, Per
A1 Tammesoo, Mari-Liis
A1 Tardif, Jean-Claude
A1 Teder-Laving, Maris
A1 Teumer, Alexander
A1 Thorgeirsson, Guðmundur
A1 Thorsteinsdottir, Unnur
A1 Torp-Pedersen, Christian
A1 Tragante, Vinicius
A1 Trompet, Stella
A1 Uitterlinden, Andre G.
A1 Ullum, Henrik
A1 van der Harst, Pim
A1 van Heel, David
A1 van Setten, Jessica
A1 van Vugt, Marion
A1 Veluchamy, Abirami
A1 Verschuuren, Monique
A1 Verweij, Niek
A1 Vissing, Christoffer Rasmus
A1 Völker, Uwe
A1 Voors, Adriaan A.
A1 Wallentin, Lars
A1 Wang, Yunzhang
A1 Weeke, Peter E.
A1 Wiggins, Kerri L.
A1 Williams, L. Keoki
A1 Yang, Yifan
A1 Yu, Bing
A1 Zannad, Faiez
A1 Zheng, Chaoqun
A1 Genes & Health Research Team
A1 DBDS Genomic Consortium
A1 Asselbergs, Folkert W.
A1 Cappola, Thomas P.
A1 Dubé, Marie-Pierre
A1 Dunn, Michael E.
A1 Lang, Chim C.
A1 Samani, Nilesh J.
A1 Shah, Svati
A1 Vasan, Ramachandran S.
A1 Smith, J. Gustav
A1 Holm, Hilma
A1 Shah, Sonia
A1 Ellinor, Patrick T.
A1 Hingorani, Aroon D.
A1 Wells, Quinn
A1 Lumbers, R. Thomas
A1 HERMES Consortium
YR 2023
UL http://medrxiv.org/content/early/2023/10/03/2023.10.01.23296379.abstract
AB Heart failure (HF), a syndrome of symptomatic fluid overload due to cardiac dysfunction, is the most rapidly growing cardiovascular disorder. Despite recent advances, mortality and morbidity remain high and treatment innovation is challenged by limited understanding of aetiology in relation to disease subtypes. Here we harness the de-confounding properties of genetic variation to map causal biology underlying the HF phenotypic spectrum, to inform the development of more effective treatments. We report a genetic association analysis in 1.9 million ancestrally diverse individuals, including 153,174 cases of HF; 44,012 of non-ischaemic HF; 5,406 cases of non-ischaemic HF with reduced ejection fraction (HFrEF); and 3,841 cases of non-ischaemic HF with preserved ejection fraction (HFpEF). We identify 66 genetic susceptibility loci across HF subtypes, 37 of which have not previously been reported. We map the aetiologic contribution of risk factor traits and diseases as well as newly identified effector genes for HF, demonstrating differential risk factor effects on disease subtypes. Our findings highlight the importance of extra-cardiac tissues in HF, particularly the kidney and the vasculature in HFpEF. Pathways of cellular senescence and proteostasis are notably uncovered, including IGFBP7 as an effector gene for HFpEF. Using population approaches causally anchored in human genetics, we provide fundamental new insights into the aetiology of heart failure subtypes that may inform new approaches to prevention and treatment.Competing Interest StatementA.Henry and R.T.L. received funding from Pfizer. J.S.W. have acted as a consultant for MyoKardia, Pfizer, Foresite Labs, and Health Lumen, and received institutional support from Bristol-Myers Squibb and Pfizer. S.d.D. was supported through grants from AstraZeneca, Roche Molecular Science/DalCor. J.R.K. declares stock ownership in AbbVie, Abbott, Bristol Myers Squibb, Johnson & Johnson, Medtronic, Merck, Pfizer. N.A.M. received speaking honoraria from Amgen and is involved in clinical trials with Ionis, Amgen, Pfizer, and Novartis. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. C.T.R. received honoraria for scientific advisory boards and consulting from Anthos, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, and received institutional research grants from Anthos, AstraZeneca, Daiichi Sankyo, Janssen and Novartis. M.S.S. received significant research grant support from Abbott Laboratories, Amgen, AstraZeneca, Bayer, Critical Diagnostics, Daiichi-Sankyo, Eisai, Genzyme, Gilead, GlaxoSmithKline, Intarcia, Janssen Research and Development, The Medicines Company, MedImmune, Merck, Novartis, Poxel, Pfizer, Quark Pharmaceuticals, Roche Diagnostics, and Takeda; and has received consulting fees from Alnylam, AstraZeneca, Bristol-Myers Squibb, CVS, Amgen. A.A.V. received consultancy fees and/or research support from AnaCardia, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Corteria, Cytokinetics, EliLilly, Moderna, Novartis, NovoNordisk, Roche Diagnostics. M-P.D. declares holding equity in Dalcor Pharmaceuticals, unrelated to this work. Members of the TIMI Study Group (ENGAGE, FOURIER, PEGASUS, SAVOR, SOLID) have received institutional research grant support through Brigham and Womens Hospital from: Abbott, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Roche, Siemens Healthcare Diagnostics, Inc., Softcell Medical Limited, The Medicines Company, Zora Biosciences, Caremark, Dyrnamix, Esperon, IFM Pharmaceuticals, MyoKardia. The authors who are affiliated with deCODE genetics/Amgen Inc. and the authors affiliated with Pfizer Inc. declare competing financial interests as employees. The remaining authors declare no competing interests. Funding StatementA.Henry was supported by the BHF Cardiovascular Biomedicine PhD studentship (FS/18/65/34186). R.T.L. and A.Henry are partly supported by a Pfizer Innovative Targets Exploration Network Grant. The project was additionally supported by BigData@Heart Consortium funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No. 116074, the UCL British Heart Foundation Accelerator (AA/18/6/34223), National Institute for Health Research University College London Hospitals Biomedical Research Centre (NIHR203328), and Health Data Research UK (MR/S003754/1). Analyses using the UK Biobank resource presented in this work were conducted under Application Numbers 9922, 15422, 12113, and 47602.  The authors thank all research participants included in the presented work. The views expressed in this work are those of the authors and not necessarily those of the funders. Additional study-level acknowledgements are provided in Supplementary Table 18.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University College London gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes